

Don R Husereau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4510174/publications.pdf>

Version: 2024-02-01

94
papers

7,557
citations

159525

30
h-index

56687

83
g-index

98
all docs

98
docs citations

98
times ranked

12195
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)â€™Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013, 16, 231-250.	0.1	1,657
2	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ, The, 2013, 346, f1049-f1049.	3.0	1,082
3	THE EFFECT OF ENGLISH-LANGUAGE RESTRICTION ON SYSTEMATIC REVIEW-BASED META-ANALYSES: A SYSTEMATIC REVIEW OF EMPIRICAL STUDIES. International Journal of Technology Assessment in Health Care, 2012, 28, 138-144.	0.2	804
4	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in Health, 2013, 16, e1-e5.	0.1	513
5	CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT. International Journal of Technology Assessment in Health Care, 2013, 29, 117-122.	0.2	281
6	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Effectiveness and Resource Allocation, 2013, 11, 6.	0.6	264
7	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value in Health, 2022, 25, 3-9.	0.1	254
8	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 2022, 25, 10-31.	0.1	251
9	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. European Journal of Health Economics, 2013, 14, 367-372.	1.4	191
10	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Medicine, 2013, 11, 80.	2.3	185
11	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ, The, 2022, 376, e067975.	3.0	141
12	Delivering precision oncology to patients with cancer. Nature Medicine, 2022, 28, 658-665.	15.2	125
13	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Pharmacoeconomics, 2013, 31, 361-367.	1.7	124
14	Priority setting for health technology assessments: A systematic review of current practical approaches. International Journal of Technology Assessment in Health Care, 2007, 23, 310-315.	0.2	114
15	Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Cmaj, 2011, 183, E1189-E1202.	0.9	112
16	A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making:Â€An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health, 2014, 17, 143-156.	0.1	96
17	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. International Journal of Technology Assessment in Health Care, 2022, 38, e13.	0.2	78
18	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health, 2019, 22, 13-20.	0.1	76

#	ARTICLE	IF	CITATIONS
19	Matching-adjusted indirect comparison of benralizumab <i>versus</i> interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1801393.	3.1	74
20	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Medicine</i> , 2022, 20, 23.	2.3	73
21	Economic evaluations of eHealth technologies: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0198112.	1.1	65
22	A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries. <i>Value in Health</i> , 2014, 17, 98-108.	0.1	57
23	Priority setting for health technology assessment at CADTH. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 341-347.	0.2	55
24	Reporting guidelines of health research studies are frequently used inappropriately. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 87-94.	2.4	52
25	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Pharmacoeconomics</i> , 2022, 40, 601-609.	1.7	39
26	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 765-770.	1.1	36
27	Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0240584.	1.1	36
28	A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development. <i>PLoS ONE</i> , 2014, 9, e90434.	1.1	35
29	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, Volume 8, 93-107.	0.8	35
30	CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 191-199.	0.2	34
31	Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. <i>Cmaj</i> , 2011, 183, E1180-E1188.	0.9	32
32	Health technology assessment in Canada. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 53-60.	0.2	30
33	HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 179-187.	0.2	30
34	Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open</i> , 2020, 10, e034463.	0.8	27
35	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 336-344.	1.1	26
36	Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs. <i>Value in Health</i> , 2014, 17, 888-894.	0.1	23

#	ARTICLE	IF	CITATIONS
37	Citation impact was highly variable for reporting guidelines of health research: a citation analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 96-104.	2.4	22
38	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Clinical Therapeutics</i> , 2022, 44, 158-168.	1.1	22
39	Wait times among patients with symptomatic carotid artery stenosis requiring carotid endarterectomy for stroke prevention. <i>Journal of Vascular Surgery</i> , 2012, 56, 661-667.e2.	0.6	20
40	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Journal of Medical Economics</i> , 2013, 16, 713-719.	1.0	18
41	Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario. <i>Journal of Vascular Surgery</i> , 2019, 70, 1469-1478.	0.6	18
42	Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics. <i>Clinical and Experimental Allergy</i> , 2020, 50, 442-452.	1.4	18
43	Trends in the utilization of endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures in Canada. <i>Journal of Vascular Surgery</i> , 2012, 56, 1518-1526.e1.	0.6	17
44	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. <i>Clinical Therapeutics</i> , 2013, 35, 356-363.	1.1	17
45	ADAPTIVE APPROACHES TO LICENSING, HEALTH TECHNOLOGY ASSESSMENT, AND INTRODUCTION OF DRUGS AND DEVICES. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 241-249.	0.2	16
46	Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. <i>Allergy, Asthma and Clinical Immunology</i> , 2018, 14, 15.	0.9	16
47	A general affinity method to purify peroxidase-tagged antibodies. <i>Journal of Immunological Methods</i> , 2001, 249, 33-41.	0.6	15
48	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. <i>Value in Health</i> , 2012, 15, 580-585.	0.1	14
49	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019, 39, 371-379.	1.2	14
50	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540.	2.0	13
51	How do we value a cure?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 551-555.	0.7	12
52	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 213.	1.0	12
53	How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States?. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 273-279.	1.0	11
54	Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2018, 36, 7-15.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Health Policy OPEN, 2022, 3, 100063.	0.5	11
56	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. Value in Health, 2022, 25, 869-886.	0.1	11
57	Long acting $\hat{1}2$ agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulmonary Medicine, 2004, 4, 7.	0.8	10
58	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Journal of Medical Economics, 2022, 25, 1-7.	1.0	9
59	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics, 2022, 23, 1309-1317.	1.4	9
60	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.2	8
61	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. Pharmacoeconomics, 2015, 33, 535-536.	1.7	7
62	Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. Applied Health Economics and Health Policy, 2018, 16, 279-288.	1.0	7
63	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. European Journal of Health Economics, 2021, 22, 723-733.	1.4	7
64	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Public Health, 2022, 22, 179.	1.2	7
65	Identifying strategies to improve diabetes care in Alberta, Canada, using the knowledge-to-action cycle. CMAJ Open, 2013, 1, E142-E150.	1.1	6
66	Using Phase-Based Costing of Real-World Data to Inform Decisionâ€“Analytic Models for Atrial Fibrillation. Applied Health Economics and Health Policy, 2016, 14, 313-322.	1.0	6
67	Editorial [Sentence First, Verdict Afterwards: Using Value of Information Analysis to Inform Decisions about Pharmacogenomic Test Adoption and Research]. Current Pharmacogenomics and Personalized Medicine, 2010, 8, 167-170.	0.2	5
68	Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. International Journal of Technology Assessment in Health Care, 2019, 35, 181-188.	0.2	5
69	Roteiro para relato de estudos de avaliaÃ§Ã£o econÃ´mica. Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2017, 26, 895-898.	0.3	5
70	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Services Research, 2022, 22, 114.	0.9	5
71	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. Current Oncology, 2021, 28, 5278-5294.	0.9	5
72	Incorporating economic evaluation into immunization decision making in Canada: a workshop. Expert Review of Vaccines, 2014, 13, 1291-1296.	2.0	4

#	ARTICLE	IF	CITATIONS
73	MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS. International Journal of Technology Assessment in Health Care, 2015, 31, 86-89.	0.2	4
74	Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: adaptación al español de la lista de comprobación CHEERS 2022. Value in Health Regional Issues, 2022, 27, 110-114.	0.5	4
75	Redefining Health Technology Assessment: A Comment on "The New Definition of Health Technology Assessment: A Milestone in International Collaboration". International Journal of Technology Assessment in Health Care, 2022, 38, .	0.2	4
76	Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists. Applied Health Economics and Health Policy, 2020, 18, 375-392.	1.0	3
77	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 146-155.	0.5	3
78	Health Technology Assessment: A Review of International Activity and Examples of Approaches With Computed Tomographic Colonography. Journal of the American College of Radiology, 2009, 6, 343-352.	0.9	2
79	Evidence and its impact on pharmacy practice: Don't be "evidence-illiterate". Canadian Pharmacists Journal, 2018, 151, 357-358.	0.4	2
80	A Beginner's Guide to Understanding Curative Therapies. Value in Health, 2019, 22, 619-620.	0.1	2
81	Priority setting for health technology assessments: A systematic review of current practical approaches. International Journal of Technology Assessment in Health Care, 2007, 23, 519-519.	0.2	1
82	Statins for primary prevention. Cmaj, 2012, 184, 791.2-792.	0.9	1
83	Health Utility Book (HUB) "Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. MDM Policy and Practice, 2019, 4, 238146831985259.	0.5	1
84	Gross profits of Canadian pharmacies: A changing policy regime. Healthcare Management Forum, 2020, 33, 228-232.	0.6	1
85	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy and Practice, 2022, 7, 238146832110610.	0.5	1
86	Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. Journal of Medical Economics, 2022, 25, 993-1004.	1.0	1
87	RR12. Trends in the Utilization of Endovascular Therapy for Elective and Ruptured Abdominal Aortic Aneurysm Procedures across Canada: A Cohort Study. Journal of Vascular Surgery, 2011, 53, 97S-98S.	0.6	0
88	Lista de Comprobación CHEERS 11 Consolidated Health Economic Evaluation Reporting Standards. en Español: Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias. Value in Health Regional Issues, 2013, 2, 335-337.	0.5	0
89	David Sackett 1934 "2015. Value in Health, 2015, 18, 549.	0.1	0
90	PC030 Device-Specific Variability in Aneurysm Sac Regression Following Endovascular Aneurysm Repair Based on a Comprehensive Registry of Patients in Eastern Ontario. Journal of Vascular Surgery, 2017, 65, 148S.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Device-Specific Variability in Aneurysm Sac Regression After Endovascular Aneurysm Repair Based on a Comprehensive Registry of Patients in Eastern Ontario. <i>Journal of Vascular Surgery</i> , 2017, 66, e73-e74.	0.6	0
92	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021, 39, 1075-1084.	1.7	0
93	Systematic review and MAIC of OCS reduction with biologic asthma treatments. , 2019, , .		0
94	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-10.	0.5	0